AAS
EIGR

Ameritas Advisory Services’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ameritas Advisory Services’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-13
Closed -$391 – 2663
2023
Q1 		$391 Buy
+13
New +$605 ﹤0.01% 2669

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Ameritas Advisory Services's EIGR Position: Q2 2023 in Review

Ameritas Advisory Services sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 13 shares — an estimated $391 sold.

Ameritas Advisory Services first reported a position in EIGR in Q1 2023 and held it in 1 quarter. The position peaked at $391 in Q1 2023. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

  • Ameritas Advisory Services reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Ameritas Advisory Services sold 13 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $391.
  • Ameritas Advisory Services first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2023 and held it in 1 quarter.
  • Ameritas Advisory Services's Eiger BioPharmaceuticals, Inc. position peaked at $391 in Q1 2023.
  • 66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Ameritas Advisory Services's 13F filing for Q2 2023, filed 25 Jul 2023.